ReviewInternational journal for parasitology. Drugs and drug resistance2021
Mefloquine as a prophylaxis for malaria needs to be revisited.
Review in International journal for parasitology. Drugs and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Long-Acting Antimalarial Drug Delivery Systems for Chemoprophylaxis: Formulation Strategies and Routes of Administration.Pharmaceutical research · 2026Review
- Systematic modeling predicts synergistic and safe drug combinations for parasitic diseases.PLoS neglected tropical diseases · 2026Article
- Comparative efficacy of free and PNAGA-encapsulated antimalarial drugs: temperature-dependent modulation ofFrontiers in pharmacology · 2026Article
- Imported Malaria Outbreak in Military Personnel Returning from Peacekeeping Operation in South Sudan - Thailand, 2023.The American journal of tropical medicine and hygiene · 2025Article
- Evaluating the Safety and Efficacy of Malaria Preventive Measures in Pregnant Women with a Focus on HIV Status: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2025Review
- In vitro synergistic effects of mefloquine combined with other antimicrobial agents on carbapenem-resistant Enterobacterales.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Targeting Malaria's Achilles' Heels: A Review of Plasmodium Life Cycle Vulnerabilities for Drug Discovery.Current topics in medicinal chemistry · 2025Review
- Novel Baicalein-Derived Inhibitors ofPathogens (Basel, Switzerland) · 2023Article
- Role of the European Pharmacist in the Implementation of the Latest WHO Guidelines for Malaria.Pathogens (Basel, Switzerland) · 2023Article
- Recent Advances in Imported Malaria Pathogenesis, Diagnosis, and Management.Current emergency and hospital medicine reports · 2023Review
- Chloroquine-Induced Psychosis: A Case Report.Cureus · 2022Article
- Hybrids of 1,4-Quinone with Quinoline Derivatives: Synthesis, Biological Activity, and Molecular Docking with DT-Diaphorase (NQO1).Molecules (Basel, Switzerland) · 2022Article
- Antimalarial prophylaxis failure: Malaria in a returning traveler despite mefloquine prophylaxis.Tropical parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to WHO, 2019 witnessed 229 million cases of malaria globally, of which Africa accounted for 94% of cases. Early diagnosis and treatment are the basis of malaria management, and the need for good chemoprophylaxis especially for people travelling to endemic areas is vital. There are a number of drug options available for the prophylaxis of malaria, mefloquine being one of the drugs used. Mefloquine has been around from the 1970s, and was developed in the United States keeping in mind the soldiers that were being deployed to areas where chloroquine resistant strains of Plasmodium were discovered. Mefloquine was preferred for its once a week dosage. Within a decade of its introduction, reports of the side effects associated with its long-term use surfaced. Mefloquine is now reported to cause a myriad of neuropsychiatric side effects including anxiety, sleep disturbance, depression, dizziness and frank psychosis, especially in patients with pre-existing psychiatric disorders. Many countries like the United States and the United Kingdom have updated their drug boxes to include the warning of these potential neuropsychiatric effects. This paper reviews the side effects of mefloquine and why there is a need to revisit its use in Indian drug policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.